Lunai Bioworks
RENB1.4200.00% ( 0.000 )
Lunai Bioworks (RENB)
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cance...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 1.420
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 21.200
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- benzinga_article · Apr 7 at 12:05 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
- prnewswire · Mar 30 at 08:02 AM
09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104
- TradingView · Feb 17 at 02:21 PM
Lunai Bioworks Inc. SEC 10-Q Report
- Unusual Whales · Feb 6 at 06:33 AM
Delonix Bioworks clears IND for DX-104 vaccine in China & Australia for MenB; Feb 6, 2026.
- Unusual Whales · Dec 9, 2025 at 06:46 AM
Lunai Bioworks discovers 3 Parkinson's subtypes, targets for $13B market. Exciting progress in precision therapeutics.
- benzinga_article · Nov 5, 2025 at 09:05 AM
Lunai Bioworks shares are trading higher after the company announced the publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines".
